# Vertex Q3 Earnings Target $500M Non-CF Revenue

> Vertex's Nov 2 earnings reveal if new therapies hit $500M non-cystic fibrosis revenue target.
- Title: Vertex Q3 Earnings Target $500M Non-CF Revenue · 24/7 Wall St.
- Summary: Vertex's Nov 2 earnings reveal if new therapies hit $500M non-cystic fibrosis revenue target. Vertex must hit $500 million in non-cystic fibrosis revenue by…
- Keywords: vertex, casgevy, journavx, trikafta, crinetics, nfl, non-cf-revenue, Earnings, Target, 500M, Non-CF, Revenue
- Source: 24/7 Wall St. — https://247wallst.com/investing/2026/10/26/the-500-million-non-cf-factor-vertex-investors-cant-ignore-on-nov-2
- Author: Rich Duprey
- Published: 2026-10-26T13:45:42+00:00
- Read time: 1 min
- Topics: vertex, casgevy, journavx, trikafta, crinetics, nfl, non-cf-revenue
## Vertex Reports Q3 Earnings
Vertex Pharmaceuticals reports third-quarter results on Nov 2 with cystic fibrosis revenue still dominant.
## Non-CF Revenue Target
Vertex aims for $500 million in non-cystic fibrosis revenue from two newer therapies by Nov 2.
## Q3 Revenue Growth
Second-quarter revenue rose 12.4% to $3.33 billion, exceeding the $3.22 billion consensus.
## CASGEVY and JOURNAVX Performance
CASGEVY revenue rose 151% to $76.4 million, and JOURNAVX revenue quadrupled to $49.6 million.
## Non-GAAP SG&A Spending
Non-GAAP SG&A rose 45% on pain and renal investments, with operating expenses at the high end of $5.65 billion to $5.75 billion.
## Full-Year Revenue Guidance
Vertex raised full-year revenue guidance to $13.10 billion to $13.20 billion after closing the Crinetics acquisition.
## Nov 30 FDA Action Date
Vertex faces Nov 30 FDA action for povetacicept in IgA kidney disease, with renal launch weeks away.
## Key takeaway

Vertex must hit $500 million in non-cystic fibrosis revenue by Nov 2 to prove it can scale beyond its core business.